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Sllmmary 
The effects of allogeneic bone marrow transplantation (BMT) on non-insulin-dependent diabetes 
mellitus (NIDDM) were examined using KK-Ay mice. KK-Ay mice reconstituted with KK-Ay 
bone marrow cells showed glycosuria, hyperinsulinemia, and hyperlipidemia. However, KK-Ay 
mice  (H-2  b)  that  had  been  lethally  irradiated  (9.0  Gy)  and  then  reconstituted  with  T 
cell-depleted bone marrow cells from normal BALB/c mice (H-2  d) showed negative urine sugar 
with decreases  in serum insulin and lipid levels 4  mo after BMT.  Morphological recovery of 
islets  and glomeruli was also noted after allogeneic BMT.  These findings suggest that BMT 
can be used to  treat not only a certain type of NIDDM but  also  its complications such as 
byperlipidemia and diabetic nephropathy. 
B 
ased on the degree of risk of patients developing ketoaci- 
dosis in the absence of insulin, diabetes mellitus has been 
classified into two types (type I, insulin-dependent diabetes 
mellitus [IDDM]; and type II, non-insulin-dependent dia- 
betes mellitus [NIDDM]). Using an animal model for IDDM 
(NOD mouse), we have demonstrated that allogeneic bone 
marrow transplantation (BMT) can be used to prevent IDDM 
(1), and that the combination of BMT and pancreas grafts 
can be used as a treatment (2). 
The etiology of NIDDM is an enigma, since various ab- 
normalities (obesity, glucose intolerance, hyperinsulinemia 
and peripheral insulin resistance, hyperlipidemia, the deposit 
of amyloid polypeptides in the islets,  the production of in- 
sulin receptor tyrosine kinase inhibitors, etc.) can be found 
in patients with NIDDM  (3). 
In this report, we examine the effects of allogeneic BMT 
on NIDDM in KK-Ay (H-2  b) mice, which are considered 
to be the animal model for NIDDM (4-10). The KK mouse 
is an inbred strain established by Kondo et al. (4) from native 
Japanese mice in 1957. Several abnormalities have been found 
in this mouse strain, including impaired glucose tolerance, 
hyperglycemia, insulin resistance of peripheral tissue, hyperin- 
sulinemia, and glomerular changes (5).  Although KK mice 
develop NIDDM, the appearance of glycosuria is influenced 
by age, sex, and season.  In 1969, Nishimura (6) introduced 
the yellow obese gene of Ay mice into the KK mice by repeat- 
edly crossing these two strains (6). The congenic mice estab- 
lished by this procedure have been termed "yellow KK" or 
"KK-Ay" mice. These mice show no sexual or seasonal varia- 
tion in the appearance of glycosuria, but show hyperglycemia 
and hyperinsulinemia at the age of 5 wk. Degranulation and 
glycogen infiltration of B cells are first observed at this age, 
followed by hypertrophy and central cavitation of islets (7). 
Renal glomerular changes, which are similar to the diffuse 
or exudative type of glomerular sclerosis in human diabetes, 
were also recognized at the age of 16 wk (8).  Insulin sensi- 
tivity of adipose tissue decreased with age and completely 
disappeared by the age of 16 wk (9,  10).  In this paper, we 
show that allogenic BMT leads to treating not only NIDDM 
in KK-Ay mice but  also  its complications,  such as hyper- 
lipidemia and diabetic nephropathy. 
Materials and Methods 
MIC~  BALB/c, C57BL/6J (B6), and KK-Ay  mice were obtained 
from CLEA Japan (Osaka). 
Bone Marrow Transplantation.  Lethally irradiated (9 Gy) KK-Ay 
mice were reconstituted with intravenous injection of 2  x  107 T 
cell-depleted bone marrow cells from 8-wk-old BALB/c (in al- 
logeneic group) and 8-wk-old KK-Ay (in syngeneic group) mice. 
In the allogeneic group,  19-wk-old KK-Ay mice with glycosuria 
(+ + + + ) were used as recipients, whereas in the syngeneic group, 
8-wk-old KK-Ay mice without glycosuria were used as recipients. 
The bone marrow cells collected from tibias and femurs of donor 
mice were pretreated with anti-Thy-l.2 mAb (F7D5; Olac, Bicester, 
England) plus rabbit complement to remove T cells. All mice were 
given tetracycline (2 mg/ml) in acidified drinking water (pH 2.7) 
for 2 wk after cell transfer. 
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from mice in allogeneic and syngeneic groups using heparinized 
PCV tubes (Monoject, St. Louis, MO). The levels of fasting blood 
sugar levels  in each group were measured 16 h after starting fasting 
using test tapes (Lilly, Indianapolis, IN) and a dextrometer.  The 
mice were intraperitoneally injected with glucose (0.5 g/kg), and 
the blood sugar levels were then measured at 30, 60, and 120 min. 
Renal Biopsy.  Mice were anesthetized with sodium pentobar- 
bital (0.05 mg/g body weight; Somnopentyl; Pitman-Moore, Inc., 
Washington Crossing, NJ). After laparotomy, small pieces of the 
renal cortex were obtained and used for immunofluorescence (IF) 
and light  microscopical studies. 
Histological Studies.  Pancreases were removed for histological 
study. They were fixed with 10% formalin, embedded in paraffin, 
and sectioned. Aldehyde fuchsin staining was carried out. Immuno- 
histochemical staining of~ cells  using the antiinsulin antibody (Dako 
Corp.,  Santa Barbara, CA, USA) was also carried out, as previ- 
ously described (2). 
Measurement of  lnsulin and Lipid Levels.  Immunoreactive insulin 
was measured using  a radioimmunoassay with the polyethylene 
glycol method, as previously described (11). Serum cholesterol and 
triglyceride levels were measured using an autoanalyzer (Hitachi, 
Tokyo, Japan). 
All experiments were performed more than three times. Each 
experiment consists of more than five mice. Because reproducible 
results were obtained,  only representative data are shown. 
Results  and  Discussion 
Nontreated KK-Ay mice showed age-dependent impaired 
glucose  tolerance  in  contrast  to  BALB/c  and  (BALB/c---~ 
C57BL/6J) mice (Fig.  1). We performed allogeneic BMT on 
19-wk-old KK-Ay (H-2  b) mice when they showed glycosuria 
(+ + + +); T cell-depleted BALB/c bone marrow cells (2  ￿ 
107  )  were injected intravenously  through  the  tail veins of 
lethally irradiated  (9 Gy) KK-Ay mice 1 d after irradiation. 
As a control group,  urine sugar-negative  8-wk-old female 
KK-Ay mice were lethally irradiated (9 Gy) and then recon- 
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Figure 1.  GTTs  in normal BALB/c, (BALB--~C57BL/6J),  and different- 
aged nontreated KK-Ay  mice: BALB/c  (e), (BALB/c--~C57BL/6J) (m), 
4-wk-old KK-Ay (O), 6-wk-old KK-Ay (rq), 8-wk-old KK-Ay (A). The 
fasting blood sugar levels were measured 16 h after starting fasting, the 
mice were  intraperitoneally injected with glucose  (0.5 g/kg), and the blood 
sugar levels were then measured after 30, 60, and 120 min. Because  each 
mouse showed similar GTT patterns, only representative data are shown. 
stituted with  2  x  107 bone marrow cells of age- and sex- 
matched KK-Ay mice. Body weight,  food and water con- 
sumption,  and urine sugar were monitored daily.  All mice 
in both groups that  received BMT  showed negative urine 
sugar 1 wk after BMT. Food and water consumption were 
similar,  and a weight loss of "~10% was observed in both 
groups 2 wk after BMT.  (KK-Ay--KK-Ay) mice showed a 
gradual appearance of glycosuria from 4 wk after BMT and 
developed urine  sugar  (+ + + +)  8 wk after BMT  (16 wk 
of age), whereas (BALB/c-+KK-Ay) mice continued to show 
negative urine  sugar.  We performed  intraperitoneal  GTTs 
monthly  on  both  groups,  starting  1  mo  after  BMT  in 
(BALB/c--KK-Ay)  mice,  and  2  mo  after  BMT  in  (KK- 
Ay--KK-Ay) mice. Fig. 2 shows the significant  difference be- 
tween  these  two  groups  in  the  glucose  tolerance  curve. 
(BALB/c---KK-Ay) mice showed negative urine sugar and a 
normal glucose tolerance curve even 4 mo after BMT. FACS  | 
analyses,  using the spleen cells of (BALB/c---KK-Ay) mice, 
revealed  that donor (H-2a)-derived cells had become domi- 
nant  (>95%).  In contrast,  glucose tolerance was abnormal 
and urine sugar positive in the (KK-Ay~KK-Ay) mice 2 mo 
after BMT. 
Significant  histological differences were also noted between 
the  two  groups.  In  aldehyde  fuchsin  staining,  the  (KK- 
Ay-~KK-Ay) mice showed hyperplastic islets with degener- 
ated B cells  (Fig.  3 A,  d),  whereas the (BALB/c---KK-Ay) 
mice showed hyperplastic islets with  active/5 cells (Fig.  3 
A, b). The islet cells in the (KK-Ay~KK-Ay) mice showed 
the same morphology as those of untreated KK-Ay mice (Fig. 
3 A, c). When the B cells were stained with antiinsulin anti- 
bodies (Dako Corp.)  the  (BALB/c~KK-Ay) mice showed 
strongly positive staining (Fig. 3 B, b), as seen in the control 
BALB/c mice (Fig. 3 B, a). The staining patterns in the (KK- 
Ay'-'KK-Ay) mice (Fig.  3 B, d) were, however, almost the 
same in the untreated KK-Ay mice (Fig. 3 B, c). These findings 
may be explained as follows: NIDDM results from an im- 
balance between insulin secretion and sensitivity.  The earliest 
detectable abnormality in NIDDM is an impairment of the 
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geneic group (O) and allogeneic group; 1 mo (A), 2 mo ((>), 3 mo (El), 
and 4 mo (V) after BMT. 
1234  Bone Marrow Transplantation Treatment of Diabetes Mellitus Figure 3.  (A) Aldehyde fuchsin 
stainings of/3 calls. Morphological 
similarities are noted in the islets be- 
tween (a) BALB/c and (b) allogeneic 
group,  or  between  (c)  untreated 
mice and (d) syngeneic group. (B) 
Immunohistochemical stainings for 
insulin. Staining patterns are similar 
to those in A. 
body's ability to respond to insulin. Therefore, the islets show 
hyperplasia to secrete insulin. However, once the insulin levels 
increase in the sen, the/3 cells do not need to secrete as much 
insulin. Thus, the pancreatic islets  of nontreated KK-Ay or 
(KK-Ay-*KK-Ay) mice show  hyperplasia but  less  insulin 
staining than normal BALB/c or (BALB/e---*KK-Ay) mice. 
This finding may alternatively be explained by the exhaus- 
tion that results from the excess secretion of insulin. 
Serum lipid and insulin levels were examined before and 
after BMT. As shown in Table 1, significant differences were 
noted between the two groups; serum lipid and insulin levels 
decreased after aUogeneic BMT. The levels were between 4- 
1235  Than et al.  Brief Definitive Report Table  1.  Serum Insulin and Lipid Levels 
Mice  Treatment  (age)  Insulin  Cholesterol  Triglyceride 
ng/ml  mg/dl  mg/dl 
BALB/c  Nontreated  0.463  +  0.313  72.33  _+  18.29  17.33  _+  16.9 
(16  wk  old) 
KK-Ay  Nontreated  3.40  ,+  0.53  85.00  ,+  11.41  18.25  ,+  28.97 
(4  wk  old) 
Nontreated  15.76  ,+  14.67  110.00  _+  11.53  287.00  ,+  58.95 
(6  wk  old) 
(KK-Ay-~KK-Ay)  Before BMT  43.201  ,+  8.150  ND  ND 
(8  wk  old) 
8  wk  after  BMT  81.157  _+  10.636  111.0  +  12.72  207.0  _+  17.66 
(16  wk  old) 
(BALB/c-*KK-Ay)  Before BMT  50.924  _+  25.597  169.25  ,+  26.32  273.5  _+  26.75 
(19  wk  old) 
4  mo  after BMT  7.727  ,+  4.088*  84.25  _+  6,02*  160.75  +  19.01" 
(9  mo  old) 
Immunoreactive insulin was measured using a radioimmunoassay with the polyethylene glycol method, as previously described (11).  The data are 
expressed  as the mean  _+  SD of 10 mice. 
" p  <0.01  vs.  the date of (BALB/c--~KK-Ay) mice before BMT. 
Figure 4.  Histopathological and immunofluorescence  microscopical  findings in the glomeruli of (BALB/c--~KK-Ay) mice before  and after BMT. 
Before BMT:  (a) the glomerulus of a KK-Ay mouse (19 wk old) shows  a diffuse increase in mesangial matrix as well as definite mesangial nodules 
(H-E staining,  x268); and (b) IgG deposits are noted in the glomerular basement membranes and mesangial matrix (IF staining,  x134). 4 mo after 
BMT: (c) the glomerulus of a KK-Ay mouse reconstituted with BALB/c bone marrow cells shows normal appearance (H-E staining,  x268); and (d) 
no IgG deposits are noted in the glomerulus of the (BALB/c-~KK-Ay)  chimeric mouse (IF staining,  x 134). 
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of normal  BALB/c mice,  since the islets still show hyper- 
plasia. This suggests that hyperlipidemia and hyperinsulinemia 
in NIDDM  are secondary to insulin  resistance. 
Glomerular changes before and after BMT were also ex- 
amined in the two groups. Before BMT, the kidneys of KK- 
Ay mice showed a global and diffuse increase in the mesan- 
gial matrix (Fig. 4 a), and a linear distribution of IgG along 
the basement membranes of glomerular capillaries  was noted 
(Fig. 4 b). However, after BMT, the (BALB/c~KK-Ay) mice 
showed normal  appearance in the H-E staining  (Fig.  4 c), 
and the IgG deposits had completely disappeared (Fig. 4 d). 
The (KK-Ay-~KK-Ay) mice, however, showed no changes 
(data not  shown). 
In this paper, we have demonstrated that BMT can be used 
to treat NIDDM in KK-Ay mice without pancreas  grafts. 
It should be noted that  hyperlipidemia,  hyperinsulinemia, 
and diabetic nephropathy  as complications  of diabetes can 
be corrected by BMT.  The possibility of a cachectic effect 
induced by BMT on reduced serum lipid and insulin levels 
can  be  excluded,  since  (KK-Ay---KK-Ay)  mice  showed 
glycosuria, hyperlipidemia, and hyperinsulinemia,  and there 
was no statistical difference in body weight between (KK- 
Ay--KK-Ay) and (BALB/c~KK-Ay) mice. The other possi- 
bility, that chronic GVHK reduced the serum lipid and in- 
sulin levels in the allogeneic group, can also be excluded, since 
neither macroscopical wasting syndrome nor microscopical 
features of chronic GVHK could be seen in any organs in 
the allogenic group. In humans, Flier et al. (12) have found 
the presence of antiinsulin receptor antibodies in some cases 
of NIDDM with insulin resistance.  Since we have demon- 
strated that autoantibodies, such as anti-DNA antibodies, rheu- 
matoid factors, and antiplatelet antibodies, are reduced after 
BMT (13-15), the most plausible explanation is that BMT 
suppresses the production  of the antiinsulin  receptor anti- 
bodies in KK-Ay mice, if antiinsulin  receptor antibodies are 
present in KK-Ay mice. We examined this possibility using 
an assay method for detecting human anti-insulin  receptor 
antibodies (11), since there is as yet no appropriate method 
for measuring mouse antiinsulin receptor antibodies. Unfor- 
tunately, we failed to obtain a positive answer. We are, how- 
ever,  in  the  process of elucidating  how BMT  can lead to 
recovery from these abnormalities. In our preliminary experi- 
ments, we have found that KK-Ay and db/db mice (another 
animal model for NIDDM) show immunological abnormal- 
ities,  and that  the abnormalities  can be corrected by BMT 
(S.  Ikehara  et al.,  manuscript  in preparation). 
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